Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.48 |
| ▸ | MEN1 | O00255 | 4/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.46 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | PDE4A | P27815 | 1/20 | 0.44 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.44 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.44 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.44 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.42 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.42 |
| ▸ | HTR5A | P47898 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4598965 | 0.88 | MEN1 (0.51) | KMT2AMEN1POLBPDCD1CD274 | |
| SCHEMBL20147971 | 0.84 | PDCD1 (0.46) | KMT2AMEN1POLBPDCD1CD274 | |
| SCHEMBL1340134 | 0.83 | AOC3 (0.53) | KMT2AMEN1POLBTSHRKDM4E | |
| SCHEMBL13067439 | 0.82 | MEN1 (0.49) | KMT2AMEN1POLBTSHRKDM4E | |
| SCHEMBL5610344 | 0.80 | PDCD1 (0.39) | PDCD1CD274KDM4EMAPTALDH1A1 | |
| SCHEMBL3393857 | 0.80 | KMT2A (0.48) | KMT2AMEN1POLBTSHRKDM4E | |
| Ether SCHEMBL27467122 | 0.79 | MEN1 (0.45) | KMT2AMEN1PDCD1CD274TSHR | |
| SCHEMBL5146259 | 0.78 | HSD17B10 (0.54) | KMT2AMEN1POLBTSHRKDM4E | |
| SCHEMBL9817534 | 0.78 | PDE4A (0.50) | KMT2AMEN1PDCD1CD274MAPT | |
| SCHEMBL34463016 | 0.77 | TAAR1 (0.52) | KMT2AMEN1POLBKDM4ETAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6989052-B1 | Phase change ink printing process | XEROX CORPORATION (US) | 2006-01-24 | — | — | US | claimed |
| US-20060004123-A1 | PHASE CHANGE INK PRINTING PROCESS | XEROX CORPORATION | 2006-01-05 | — | — | US | claimed |
| EP-2423199-A1 | Substituted imidazoles and their use as pesticides | Pfizer Limited (GB) | 2012-02-29 | — | — | EP | disclosed |
| CN-101906106-A | New heterogeneous ring compound as the HSP90-inhibitor | CONFORMA THERAPEUTICS CORP | 2010-12-08 | — | — | CN | disclosed |
| US-7825149-B2 | Substituted imidazoles | PFIZER LIMITED (GB) | 2010-11-02 | — | — | US | disclosed |
| CN-1882589-B | Novel heterocyclic compounds as HSP 90-inhibitors | CONFORMA THERAPEUTICS CORP | 2010-06-09 | — | — | CN | disclosed |
| EP-2145888-A1 | Deazapurine derivatives as HSP90-Inhibitors | Conforma Therapeutics Corporation (US) | 2010-01-20 | — | — | EP | disclosed |
| US-20090312326-A1 | SUBSTITUTED IMIDAZOLES | PFIZER LIMITED (GB) | 2009-12-17 | — | — | US | disclosed |
| US-7592362-B2 | Substituted imidazoles | PFIZER LIMITED (GB) | 2009-09-22 | — | — | US | disclosed |
| US-7547718-B2 | Substituted imidazoles | PFIZER LIMITED (GB) | 2009-06-16 | — | — | US | disclosed |
| US-7544706-B2 | Substituted imidazoles | PFIZER LIMITED (GB) | 2009-06-09 | — | — | US | disclosed |
| US-20070185064-A1 | 2-Aminopurine Analogs Having HSP90-Inhibiting Activity | CONFORMA THERAPEUTICS CORPORATION (US) | 2007-08-09 | — | — | US | disclosed |
| US-20070167506-A1 | SUBSTITUTED IMIDAZOLES | PFIZER INC. (US) | 2007-07-19 | — | — | US | disclosed |
| CN-1882589-A | Novel heterocyclic compounds as HSP 90-inhibitors | CONFORMA THERAPEUTICS CORP (US) | 2006-12-20 | — | — | CN | disclosed |
| US-7138401-B2 | 2-aminopurine analogs having HSP90-inhibiting activity | CONFORMA THERAPEUTICS CORPORATION (US) | 2006-11-21 | — | — | US | disclosed |
| EP-1670802-A2 | NOVEL HETEROCYCLIC COMPOUNDS AS HSP90-INHIBITORS | Conforma Therapeutic Corporation (US) | 2006-06-21 | — | — | EP | disclosed |
| US-6989052-B1 | Phase change ink printing process | XEROX CORPORATION (US) | 2006-01-24 | — | — | US | disclosed |
| US-20060004123-A1 | PHASE CHANGE INK PRINTING PROCESS | XEROX CORPORATION | 2006-01-05 | — | — | US | disclosed |
| US-20050113340-A1 | 2-Aminopurine analogs having HSP90-inhibiting activity | CONFORMA THERAPEUTICS CORPORATION | 2005-05-26 | — | — | US | disclosed |
| WO-2005028434-A2 | NOVEL HETEROCYCLIC COMPOUNDS AS HSP90-INHIBITORS | CONFORMA THERAPEUTICS CORPORATION (US) | 2005-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312326-A1 | SUBSTITUTED IMIDAZOLES | ABL1, TYR, CYP3A4 | KMT2A 945/4885MEN1 493/4885POLB 3099/4885 |
| US-20050113340-A1 | 2-Aminopurine analogs having HSP90-inhibiting activity | HSP90AB2P, HSP90AB1, HSP90AA1 | KMT2A 2392/4885MEN1 4060/4885POLB 890/4885 |
| US-20070167506-A1 | SUBSTITUTED IMIDAZOLES | ABL1, TYR, CYP3A4 | KMT2A 945/4885MEN1 493/4885POLB 3099/4885 |
| US-20070185064-A1 | 2-Aminopurine Analogs Having HSP90-Inhibiting Activity | HSP90AB2P, HSP90AB1, HSP90AA1 | KMT2A 2392/4885MEN1 4060/4885POLB 890/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.